I had the honor of interviewing Dr. Racheli Ofir, Vice President (VP) of Research & Intellectual Property at Pluristem Therapeutics. Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, three-dimensional technology platform to develop cell therapies for a broad range of diseases.

The company is at the forefront of placental-based cell therapy applications. In addition to other accomplishments, the company is now preparing for a proposed Phase III trial of its PLX-PAD cells in the treatment of critical limb ischemia (CLI). [Read more…]